|
Forecast
Period
|
2026-2030
|
|
Market
Size (2024)
|
USD
4.03 Billion
|
|
Market
Size (2030)
|
USD
8.50 Billion
|
|
CAGR
(2025-2030)
|
13.21%
|
|
Fastest
Growing Segment
|
Instruments
|
|
Largest
Market
|
North
America
|
Market Overview
Global Automated Cell Counting Market was valued at
USD 4.03 Billion in 2024 and is expected to reach USD 8.50 Billion by 2030 with
a CAGR of 13.21% during the forecast period. The global automated cell
counting market is being driven by several key factors, including the growing
demand for precise and efficient cell analysis in various industries such as
biotechnology, pharmaceuticals, and clinical diagnostics. Advancements in
technology, particularly the integration of artificial intelligence and machine
learning, are enhancing the accuracy, speed, and reliability of automated cell
counting systems. These innovations are replacing traditional manual methods,
offering increased throughput and reduced human error. The rising prevalence of
chronic diseases, cancer, and infectious diseases has amplified the need for
rapid and accurate cell counting for diagnostics and research. The increasing
focus on personalized medicine and drug development is further driving the
demand for automated cell counting solutions.
Key Market Drivers
Technological Advancements and Integration of
Artificial Intelligence (AI)
The integration of artificial intelligence (AI),
machine learning (ML), and automation in cell counting technologies is a
significant driver of the global automated cell counting market. These
innovations enable substantial improvements in speed, accuracy, and efficiency
compared to traditional manual counting methods. Manual cell counting is prone
to human error and is time-consuming, especially when handling large samples.
AI-powered automated systems, however, eliminate human biases and perform cell analysis
more quickly and accurately. In May 2023, Sysmex introduced the Sample
Preparation System PS-10, the Clinical Flow Cytometry1 system Flow Cytometer
XF-1600, along with antibodies and other products in Japan. The company also
expanded the launch of these products to the Asia Pacific, North America, and
Europe regions. By incorporating monoclonal antibody reagents, the entire flow
cytometry process can now be fully automated.
Machine learning algorithms analyze vast datasets
to identify patterns, anomalies, and cellular characteristics, which could be
missed during manual observation. AI-based systems can differentiate between
various cell types, such as red blood cells, white blood cells, and stem cells,
leading to more reliable results. These systems are capable of providing
real-time data analysis and feedback, allowing researchers to make swift,
informed decisions. As AI continues to evolve, the systems become smarter, more
precise, and adaptable to specific research needs, driving demand for automated
cell counting technologies across biotechnology, pharmaceutical, and clinical
diagnostics sectors. In drug development, particularly for oncology and
immunology, the ability to perform high-throughput analysis with minimal errors
and time loss is paramount, thereby fueling market growth.
Increased Demand for Personalized Medicine
The rise of personalized medicine has significantly
influenced the demand for automated cell counting technologies. Personalized
medicine tailors treatment plans based on individual genetic profiles,
lifestyle, and specific disease characteristics. As precision medicine becomes
more popular, there is an increasing need for high-resolution cellular
analysis. Automated cell counting technologies allow researchers and healthcare
professionals to evaluate individual cell behaviors, properties, and interactions
with different drugs, which is essential for developing patient-specific
treatments. For example, cancer therapies can be more effective when
personalized based on the type of cancer cells and their response to various
treatment regimens. In January 2024, Abzena introduced its new cell line development
platform, AbZelectPRO. This program is designed to accelerate the development
of cell lines for the production of recombinant proteins and antibodies.
Automated systems enable detailed analysis of cell
lines, tumor microenvironments, and immune responses, providing critical data
that supports the personalization of medical treatments. This growing demand
for personalized therapies is a major factor propelling the adoption of
automated cell counting systems in clinical settings, biotechnology labs, and
pharmaceutical research.
Increasing Prevalence of Chronic Diseases and
Cancer
The growing prevalence of chronic diseases,
particularly cancer, is another important driver of the automated cell counting
market. Cancer, in particular, requires frequent monitoring and analysis of
cells for diagnosis, prognosis, and treatment evaluation. Automated cell
counters are critical in analyzing cell samples from patients with cancer,
enabling researchers to measure cell proliferation, apoptosis (cell death), and
overall tumor growth. The United States Cancer Statistics (USCS) represent the official
federal data on cancer. In 2021, 1,777,566 new cancer cases were reported in
the United States. In 2022, cancer claimed the lives of 608,366 individuals in
the country.
These
systems also provide faster and more accurate assessments of cancer cells,
which is crucial for developing targeted therapies. Chronic diseases such as
diabetes and cardiovascular disorders often require regular cell-based testing
for management and therapeutic adjustments. As the global incidence of these
diseases continues to rise, the demand for precise and efficient cell counting
in diagnostics and research is increasing. Automated systems can be employed in
drug discovery, where high-throughput screening is required to identify new
compounds that target specific disease-related cells, further driving the need
for automated cell counting in both clinical and research applications.
Growing Research and Development in Biotechnology
and Pharmaceuticals
The biotechnology and pharmaceutical industries are
some of the biggest contributors to the growth of the automated cell counting
market. In these industries, cell-based assays are essential for understanding
disease mechanisms, drug efficacy, and safety profiles. With the rising demand
for new therapeutic agents and vaccines, high-throughput screening of cell
cultures is necessary to accelerate drug discovery and development. In January 2024, Pluri
Inc., a biotechnology company, introduced a new business division as PluriCDMO
(Contract Development and Manufacturing Organization). This division aims to
provide cell therapy manufacturing services at a 47,000 sq. ft. GMP-certified
cell therapy production facility. It is designed to assist customers in
overcoming challenges encountered during the development and manufacturing of
cell therapies.
Automated cell counters offer a way to quickly and
accurately measure the effects of new drug compounds on cultured cells,
reducing the time spent on manual methods and increasing overall productivity.
Automated systems are crucial for tasks such as measuring cell viability,
growth rates, and cell morphology, which are necessary to identify promising
drug candidates. As the pharmaceutical industry moves toward biologic drugs and
monoclonal antibody therapies, the need for precise cellular analysis is further
amplified. The increased focus on personalized therapeutics, coupled with
advancements in cell-based research techniques, has fueled investments in
automated cell counting solutions, making them indispensable in the R&D
pipeline.
Global Expansion of Healthcare and Research
Facilities
The global expansion of healthcare infrastructure,
particularly in emerging markets, is contributing to the growth of the
automated cell counting market. Countries in Asia Pacific, South America, and
the Middle East are investing in healthcare systems and research facilities,
with a strong focus on improving diagnostics and research capabilities. As
these regions develop their healthcare infrastructure, the demand for advanced
technologies, such as automated cell counting systems, is increasing. The
rising adoption of cell-based therapies and advanced diagnostics in these
regions is encouraging healthcare providers to implement automation in their
laboratories and research centers. The ability to offer accurate and efficient
cell analysis is becoming a key factor in improving healthcare outcomes in both
clinical and research settings. As the number of healthcare and research
facilities grows worldwide, so does the demand for reliable, automated cell
counting technologies, thereby driving market expansion.
Download Free Sample Report
Key Market Challenges
High Initial Cost of Automated Cell Counting
Systems
One of the major challenges hindering the
widespread adoption of automated cell counting systems is the high initial
cost associated with these technologies. Automated systems, particularly
those with advanced features such as AI integration, high-throughput
capabilities, and real-time analysis, require significant investment. This
upfront cost can be a barrier for smaller laboratories, research facilities,
and healthcare centers, especially in emerging markets or regions with limited
healthcare budgets. Maintenance and software upgrades also contribute to the
overall cost of ownership, making it less financially feasible for some
organizations. While these systems can increase efficiency and accuracy over
time, the high cost remains a significant obstacle, particularly in
price-sensitive markets. As a result, many smaller organizations continue to
rely on traditional manual counting methods, which are more affordable but less
efficient.
Technical Complexity and Training Requirements
Automated cell counting systems, especially those
that utilize advanced technologies such as AI and machine learning, require a
high level of technical expertise to operate effectively. This complexity
often necessitates specialized training for laboratory technicians and
healthcare professionals. Without proper training, users may not fully exploit
the capabilities of the systems, leading to inefficiencies or errors in
results. Troubleshooting technical issues or software malfunctions can require
specialized knowledge and expertise, which can delay operations or result in
system downtime. As these automated systems evolve and incorporate more
sophisticated features, the gap between their capabilities and user competency
may widen, posing a challenge for organizations seeking to maximize their
investment in these technologies. Ensuring comprehensive training programs and
support services is crucial for successful implementation and adoption of these
systems.
Limited Adaptability to Complex Cell Types and
Samples
While automated cell counting systems have made
significant strides in handling a wide range of cell types, there are still
limitations when it comes to more complex or heterogeneous cell samples.
Cells in three-dimensional (3D) cultures, stem cell populations, or mixed cell
populations can exhibit varied morphologies, making accurate counting and
classification more challenging. Traditional automated systems may struggle to
differentiate between different cell types in a sample, particularly when cell
size, shape, or behavior is non-standard or atypical. In certain clinical
settings, cells may be present in very low concentrations, further complicating
detection. These limitations can impact the reliability of results, especially
in research areas such as stem cell therapy or cancer immunotherapy, where
precise and accurate cell characterization is critical. While there are ongoing
advancements in technology, overcoming these challenges to improve the
adaptability of automated systems to complex cell types is an ongoing issue for
the market.
Key Market Trends
Improvement in Cell Culture Technologies
Cell culture technology is essential in drug
development, tissue engineering, and gene therapy. Automated cell counting
systems play a vital role in these applications by providing accurate and
consistent data on cell culture conditions. Cell culture processes often
involve culturing large numbers of cells, which can be challenging to monitor
manually. Automated systems ensure real-time tracking of cell growth,
morphology, and viability, providing reliable data that allows researchers to
optimize culture conditions. As cell culture techniques continue to improve and
become more complex, automated cell counters are evolving to meet these needs,
offering solutions for multicellular spheroids, 3D cultures, and organoid
models. These advancements enable more efficient scaling of experiments and
more accurate monitoring of cultured cells. The growing reliance on cell
cultures for drug testing, vaccine production, and regenerative medicine is
driving the demand for automated counting systems that can keep pace with these
advances and ensure high-quality results.
Increased Focus on Stem Cell Research
Stem cell research is one of the most promising
fields in medicine, offering potential treatments for a variety of conditions,
including neurodegenerative diseases, heart disease, and genetic disorders.
Accurate and efficient cell counting is particularly crucial in stem cell
research to track cell differentiation, proliferation, and the formation of new
tissues. Automated cell counting technologies offer significant advantages in
stem cell studies, enabling researchers to monitor stem cell behavior in
real-time and on a large scale. These systems can measure cell density, cell
cycle progression, and stem cell viability, providing invaluable data to
researchers working in regenerative medicine. As the interest in stem cell
therapies continues to grow, the demand for automated systems that can handle
complex cell populations and provide accurate counts is expected to rise,
fueling the market for automated cell counters.
Advances in Cell-Based Assays
Cell-based assays are essential tools in research,
diagnostics, and drug development, offering insights into cellular functions,
disease pathways, and treatment mechanisms. Automated cell counting systems
enhance the efficiency and accuracy of these assays by providing reliable,
reproducible data on cell populations. With the increased use of cell-based
assays in pharmaceutical and biotechnology industries, particularly in
high-throughput screening and toxicity testing, the need for automation has
grown. Automated cell counters are designed to handle large sample volumes,
streamline workflows, and deliver rapid results, which are essential in
environments where time and accuracy are critical. The development of multiplex
assays, which assess multiple parameters simultaneously, requires precise cell
counting to ensure the quality and consistency of results. The growth of these
advanced assay techniques in drug discovery and disease modeling is therefore
driving the adoption of automated cell counting technologies.
Segmental Insights
Product Insights
Based on the product, instruments
segment was dominating, with a significant share of the overall
market. This dominance is primarily due to the increasing adoption of advanced
automated systems that are designed to enhance cell counting efficiency,
accuracy, and throughput in various research and clinical applications. The instruments
include fully automated cell counters, imaging systems, and specialized
platforms equipped with advanced technologies such as fluorescence, microscopy,
and artificial intelligence (AI) to process complex cell samples. These systems
enable faster, more reliable, and more accurate cell counting, which is
essential in drug development, clinical diagnostics, and biotechnology
research.
The shift toward automation in laboratory and
research settings has led to the growing need for sophisticated instruments
that can handle high volumes of cell samples while maintaining precision.
Traditional methods of manual cell counting, which are labor-intensive,
time-consuming, and prone to human error, have pushed researchers and
clinicians toward automated solutions. Instruments that offer automated
processes for cell analysis, such as automated flow cytometry or imaging-based
cell counters, are essential for high-throughput screening in research labs and
clinical laboratories, where cell viability, morphology, and other parameters
must be measured quickly and accurately. As the demand for precision medicine
grows, the need for such instruments becomes even more critical, further
contributing to their dominance in the market.
In addition, advancements in instrument
technology have made these systems more user-friendly, efficient, and
reliable. The integration of artificial intelligence and machine learning
algorithms into cell counting instruments has enhanced their capabilities,
allowing them to perform tasks such as identifying and classifying different
cell types, measuring cell viability, and detecting cellular abnormalities with
greater accuracy. The growing interest in cell-based therapies, personalized
medicine, and stem cell research is driving the demand for highly sophisticated
and automated cell counting instruments that can cater to the specific needs of
researchers and healthcare providers. These instruments are not only increasing
the speed of cell counting but also reducing the possibility of errors, leading
to more consistent and reliable results.
End Use Insights
Based on the end use
segment, pharmaceutical and biotechnology companies was the
dominant segment in the global automated cell counting market. This dominance
can be attributed to the increasing reliance on these advanced systems for drug
discovery, development, and testing, which are crucial processes within the pharmaceutical
and biotechnology industries. Automated cell counting systems are essential for
high-throughput screening, cell viability assays, and analysis of cell
responses to various treatments, all of which are key steps in the development
of new therapeutic agents. The ability to automate cell counting significantly
reduces time and labor costs while improving accuracy and consistency in
results, which is crucial in drug research and clinical trials.
Pharmaceutical companies are increasingly using
automated cell counting systems to assess the effects of potential drug
candidates on cell cultures, which accelerates the identification of promising
compounds and streamlines the drug development process. Cell counting systems
are also employed in the production of biologics, including monoclonal
antibodies, vaccines, and cell-based therapies. As the demand for biologic
drugs continues to grow, pharmaceutical companies are investing in automated
cell counters to improve the efficiency of cell-based assays, which are
critical in assessing the quality and potency of biologics. Pharmaceutical
companies involved in gene therapy and immunotherapy rely on automated cell
counting to monitor cell populations and ensure that the treatments are
effective in altering or modifying target cells.
Download Free Sample Report
Regional Insights
North America was dominating the global automated cell counting market, and
this can be attributed to several key factors such as the region’s strong
healthcare infrastructure, high adoption rates of advanced technologies, and
substantial investments in research and development. The United States, in
particular, plays a leading role within North America due to its
well-established pharmaceutical, biotechnology, and healthcare industries.
These sectors are among the largest consumers of automated cell counting systems,
as they rely heavily on these technologies for drug discovery, clinical
diagnostics, and biotechnology research.
North America benefits from a robust healthcare
ecosystem that includes world-renowned pharmaceutical companies, research
institutes, and hospitals that frequently adopt cutting-edge technologies to
streamline operations and improve research and diagnostic outcomes.
Pharmaceutical and biotechnology companies in the region increasingly turn to
automated cell counting systems to enhance the efficiency of their drug
development processes, particularly for high-throughput screening and cell
viability assays. With the increasing focus on biologics, personalized
medicine, and cell-based therapies, the need for advanced cell counting systems
has grown significantly in recent years. Automated cell counters are essential
for accelerating the development of these therapies, making them a crucial part
of the research and development efforts in the region.
North America has a high concentration of research
and academic institutions, such as universities and private research centers,
that contribute significantly to the demand for automated cell counting
systems. These institutions are at the forefront of innovation in biomedical
research, particularly in fields like stem cell research, cancer immunotherapy,
and gene therapy. As such, the demand for automated systems to support cell
analysis is continually growing. With a high level of technological innovation
and access to advanced tools, researchers in the region can leverage automated
systems to expedite experimental processes, contributing to the overall market
demand.
Recent Developments
- In October 2023, DeNovix's CellDrop Automated Cell
Counter became the first approved automated cell counter under the ACT Label
certification by My Green Lab.
- In November 2023, Revvity
introduced the T-SPOT®.TB test for latent tuberculosis (TB) screening in India.
This test, based on ELISPOT technology, is the only FDA-approved commercially
available intron gamma release assay. ELISPOT technology involves the washing,
isolation, and counting of peripheral blood mononuclear cells from whole blood,
offering reproducible results for TB detection.
- In October 2023, DeNovix
Inc. launched its DeNovix CellDrop Automated Cell Counter, which received ACT®
Label certification from My Green Lab®. It became the first automated cell
counter to achieve this certification. The device carries the ACT Environment
Impact Factor Label, which helps scientists make more sustainable decisions
regarding manufacturing practices, energy and water use, and product content.
- In July 2024, Bioserve India unveiled its advanced
stem cell products in India. This launch aims to support drug development and
scientific research, marking a significant step forward in therapeutic
discovery and regenerative medicine.
Key Market Players
- Danaher Corporation
- Thermo Fisher Scientific Inc.
- Merck KgaA
- Countstar, Inc.
- Bio-Rad Laboratories, Inc.
- F. Hoffmann-La Roche Ltd
- Chemometec A/S
- Olympus Corporation
- Sysmex Corporation
- Agilent Technologies, Inc.
|
By Product
|
By Application
|
By End Use
|
By Region
|
- Instruments
- Consumables
& Accessories
|
- Blood
Analysis
- Stem Cell
Research
- Cell Line
development
- Others
|
- Pharmaceutical
& Biotechnology Companies
- Hospitals
& Diagnostic laboratories
- Research
& Academic Institutes
- Others
|
- North
America
- Europe
- Asia Pacific
- South
America
- Middle East
& Africa
|
Report Scope:
In this report, the Global Automated Cell Counting Market
has been segmented into the following categories, in addition to the industry
trends which have also been detailed below:
- Automated Cell Counting Market, By Product:
o Instruments
o Consumables &
Accessories
- Automated Cell Counting Market, By Application:
o Blood Analysis
o Stem Cell Research
o Cell Line development
o Others
- Automated Cell Counting Market, By End Use:
o Pharmaceutical &
Biotechnology Companies
o Hospitals & Diagnostic
laboratories
o Research & Academic
Institutes
o Others
- Automated Cell Counting Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Automated
Cell Counting Market.
Available Customizations:
Global Automated Cell Counting market report
with the given market data, TechSci Research offers customizations according to
a company's specific needs. The following customization options are available
for the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
Global Automated Cell Counting Market is an
upcoming report to be released soon. If you wish an early delivery of this
report or want to confirm the date of release, please contact us at [email protected]